Gilead CEO Sells $1.4 Million in Shares, Retains Significant Stake

On January 28, Daniel O’Day, Chairman and CEO of Gilead Sciences, Inc. (NASDAQ: GILD), sold 10,000 shares in the open market under a pre-established Rule 10b5-1 trading plan, realizing approximately $1.4 million (around KRW 1.8 billion) in proceeds.

Earlier on January 15, Gilead’s Chief Commercial Officer and Chief Financial Officer also executed sales of their own shares under 10b5-1 plans. All three executives retain holdings in the hundreds of thousands of shares following these transactions.

In its first and second quarters of 2025, Gilead’s core business revenues excluding Veklury grew 4% year-over-year, driven by strong demand for its HIV treatments. This momentum has contributed to higher product sales and an upward revision of the company’s full-year guidance.

In June 2025, the U.S. Food and Drug Administration approved YesTuGo, a semiannual, lenacapavir-based HIV prevention injection, expanding Gilead’s HIV prevention portfolio and reinforcing future growth drivers.

Headquartered in Foster City, California, Gilead is a global biopharmaceutical company operating in more than 35 countries, with a focus on therapies for HIV, viral hepatitis, COVID-19, oncology and inflammatory diseases.

In its recent earnings announcement, CEO O’Day stated that Gilead will pursue medium- to long-term growth centered on its HIV franchise, lenacapavir and the oncology candidate Trodelvy, while maintaining a balance between research and development investment and shareholder returns.